• Co-Diagnostics entered an inducement deal for holders to cash-exercise existing warrants for 1,702,362 shares at USD 1.57 each.
• Transaction includes issuance of new warrants for 3,404,724 shares at USD 1.56, exercisable only after required Nasdaq stockholder approval.
• Gross proceeds expected at about USD 2.67 million; closing targeted for about Aug. 3, 2026.
• Shares underlying the existing warrants are already registered; a resale registration statement is required for shares underlying the new warrants.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-035553), on July 31, 2026, and is solely responsible for the information contained therein.